A fascinating virtual talk with Dr Soma Sengupta where she discussed leveraging a neurotransmitter receptor in cancers, with a historical slant.
Dr Soma Sengupta completed her MD-PhD at the University of Cambridge. She received Membership in the Royal College of Physicians in the UK before moving to the U.S. for an internship in medicine where she had residency in Neurology, Beth Israel Deaconess Medical Center-Harvard. Dr Sengupta then had clinical and research fellowships at Massachusetts General Hospital, Boston Children’s Hospital, Dana-Farber Cancer Institute, and Brigham and Women’s Hospital. She is board certified in Neurology and Neuro-Oncology, and recently was elected as a Fellow of the Royal College of Physicians.
Dr Sengupta's Post-doctoral research training included a fellowship at Yale with Professor Carolyn Slayman, immunology research at the Cambridge Institute of Medical research with Dr. Paul Lehner, and in pediatric brain tumor research with Drs. Scott Pomeroy at Boston Children’s Hospital and Frances Jensen, who is currently Chair, Dept. Neurology, University of Pennsylvania.
Dr Sengupta was an attending at BIDMC-Harvard in neuro-oncology before moving to Emory University and the Winship Cancer Institute. She has a long-standing research interest in membrane transport proteins and a major part of her lab is studying such proteins as anti-cancer targets as well as their role in development of disparate cancers. Clinically, Dr Sengupta manages adult brain tumours and adult survivors of pediatric brain cancers. She has a strong clinical interest in investigator-initiated trials to bring much needed new treatments for these patient populations.
